ProCE Banner Activity

Strategies for Optimal HIV Treatment and Prevention: Answering the Questions on Considering an ART Switch During Pregnancy

Multimedia

Hear from expert faculty as they answer questions and discuss key considerations when determining whether and how to switch antiretroviral therapy in pregnant people with HIV.

Released: November 23, 2022

Expiration: November 22, 2023

No longer available for credit.

Share

Faculty

Annette Haberl

Annette Haberl, MD

Physician
Head of HIV and Women, HIVCENTER Frankfurt
Department of Infectious Diseases
Hospital of the Johann Wolfgang Goethe-University
Frankfurt, Germany

William R. Short

William R. Short, MD, MPH, FIDSA

Associate Director of the HIV Clinical Trials Unit
Associate Professor of Medicine and Obstetrics and Gynecology
Division of Infectious Diseases
Perelman School of Medicine
University of Pennsylvania
Philadelphia, Pennsylvania

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner

Supporters

Supported by educational grants from

Gilead Sciences, Inc.

ViiV Healthcare

Faculty Disclosure

Primary Author

Annette Haberl, MD

Physician
Head of HIV and Women, HIVCENTER Frankfurt
Department of Infectious Diseases
Hospital of the Johann Wolfgang Goethe-University
Frankfurt, Germany

Annette Haberl, MD: consultant/advisor/speaker: Gilead Sciences, Janssen-Cilag, Merck Sharpe and Dohme, ViiV Healthcare.

William R. Short, MD, MPH, FIDSA

Associate Director of the HIV Clinical Trials Unit
Associate Professor of Medicine and Obstetrics and Gynecology
Division of Infectious Diseases
Perelman School of Medicine
University of Pennsylvania
Philadelphia, Pennsylvania

William R. Short, MD, MPH, AAHIVS: non-CME/CE services: Janssen; consultant/advisor/speaker: ViiV.